1,3-Dioxane Carboxylic Acids for Metabolic Disorder Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hyperlipidemia, diabetes, and obesity often come with side effects such as hypoglycemia, liver toxicity, and tumor-inducing potential, necessitating a safer and more effective drug that can manage insulin resistance and hyperlipidemia without severe adverse effects.
Innovation Solution
Development of novel substituted 1,3-dioxane carboxylic acids and their derivatives, which act as hypocholesterolemic, hypolipidemic, and antihyperglycemic agents, potentially offering additional weight-lowering effects and improved treatment outcomes for Syndrome X, atherosclerosis, and related metabolic disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for hyperlipidemia and diabetes are used, then blood glucose and lipid levels are lowered, but severe side effects such as hypoglycemia, liver toxicity, and tumor-inducing potential occur
Solution Approach 1:
The patent applies parameter changes by developing novel substituted 1,3-dioxane carboxylic acid derivatives with modified chemical structures and properties. These compounds represent a new class of PPAR agonists with altered molecular parameters that achieve therapeutic effects while reducing adverse reactions compared to existing drugs
Solution Approach 2:
The invention employs composite material principles by creating dual PPAR alpha and gamma agonists that combine the beneficial effects of both receptor activations. This composite approach allows simultaneous improvement of lipid metabolism and glucose control with enhanced safety profile
2Reliability
If higher dosages are used to achieve better treatment outcomes, then metabolic parameters are improved, but side effects increase
Solution Approach 1:
The patent utilizes parameter changes by optimizing the chemical structure of 1,3-dioxane carboxylic acid derivatives to achieve high potency at lower dosages. The modified molecular parameters enable effective PPAR activation with reduced drug concentrations, thereby improving efficacy while minimizing dose-dependent side effects
3Reliability
If conventional drug therapies are administered, then insulin resistance and hyperlipidemia are managed, but liver toxicity and tumor-inducing potential arise
Solution Approach 1:
The patent applies the extraction principle by isolating and optimizing specific molecular features of PPAR agonists that provide metabolic benefits while removing or minimizing structural elements associated with hepatotoxicity and tumorigenicity. This selective extraction creates safer therapeutic agents
Solution Approach 2:
The invention employs short-acting or reversible binding characteristics in the 1,3-dioxane derivatives, allowing controlled PPAR activation that can be quickly terminated if adverse effects occur, providing a safety mechanism against cumulative toxicity
Data Source
AI summary
The present invention relates to novel 1,3-dioxane carboxylic acids of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation.